#patientchat Transcript
Healthcare social media transcript of the #patientchat hashtag.
– ().
See #patientchat Influencers/Analytics.
| Profile | Tweet |
|---|---|
 | Patient Chat @patientchat Welcome to #patientchat - where patients, care partners, and advocates come to learn from each other and discuss topics of interest |
 | Alan Brewington @abrewi3010 RT @patientchat: Welcome to #patientchat - where patients, care partners, and advocates come to learn from each other and discuss topics of interest |
 | Science 37 @Science37x RT @patientchat: Join us in a few minutes for the Empowered #patientchat. Info/Topics: Join us in a few minutes for the Empowered #patientchat. Info/Topics: https://t.co/lRhU0PEGMz #patientchat |
| Science 37 @Science37x RT @patientchat: Learn more about the Empowered #patientchat series and how to participate here: Learn more about the Empowered #patientchat series and how to participate here: https://t.co/9m9nTL83Mi |
| Science 37 @Science37x RT @patientchat: New to tweet chats? Follow hashtag #patientchat and include it in every tweet during the next hr. You can engage w/others on the topic. |
| Patient Chat @patientchat We start out with introductions - Those joining in, please take a moment to introduce yourself. #patientchat |
 | Healthcare Scene @HealthcareScene RT @power4patients: Gotta run and get ready for #patientchat, thank you for a great #HITsm chat @HealthcareScene |
 | Heather McCullen @H_SalemOaks Hi #patientchat. Joining from Ann Arbor(-ish) representing @SalemOaks. |
| Patient Chat @patientchat I’m Kara from @power4patients and I’m excited to be moderating today’s #patientchat on #ClinicalTrials |
 | Dr. Phyllisa Deroze @not_defeated I'm looking forward to my first #patientchat |
 | Shereese Maynard, MS; MBA 😷 She/Her @ShereeseMayMba Hello all. I'm Shereese from Maryland #patientchat https://t.co/GEgbYz1bpl |
| Science 37 @Science37x RT @patientchat: Welcome to #patientchat - where patients, care partners, and advocates come to learn from each other and discuss topics of interest |
 | Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 @gratefull080504 checking in from Chicago President Voice of the Patient I have spent over 2 years professional building awareness of #raredisease clinical trial #patientchat https://t.co/idb4PYbvi5 |
| Patient Chat @patientchat Please continue intros and welcomes. I’ll share a couple “ground rules" :) #patientchat |
 | Barby Ingle Official @BarbyIngle I am @BarbyIngle. I am an ambassador for #cureclick and #HeroLinx clinical trial coordinators to help raise awareness about current trials being conducted for #ChronicPain diseases. #patientchat https://t.co/lOsTx3uq8V |
 | Tebra @TebraOfficial Hello #PatientChat @GoKareo stopping by the chat today |
| Patient Chat @patientchat Today's chat is solely informational and not a substitute for speaking w/a doctor who's familiar w/your medical needs & history #patientchat |
| Alan Brewington @abrewi3010 Alan here. I’m a #rheum #chronicpain #mentalhealth patient who has a #photography habit as part of my story. #patientchat https://t.co/Ega80UzF2H |
 | Nerdy Zebra @nerdymedzebra RT @patientchat: Welcome to #patientchat - where patients, care partners, and advocates come to learn from each other and discuss topics of interest |
 | Richard Kreis @kreisr1 Teifecta Richard here, i care for mom (cardiac, pulmonary), BIL (epilepsy) and self (RCPS). Looking for a great chat. #patientchat #patientchat |
| Richard Kreis @kreisr1 RT @patientchat: Today's chat is solely informational and not a substitute for speaking w/a doctor who's familiar w/your medical needs & history #patientchat |
 | Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey HAAAAIIII - Casey Q here, calling in from Jimbobwe, uh, Richmond VA. Health literacy + science maven. Write about #clinicalresearch + #citizenscience frequently. #patientchat |
| Nerdy Zebra @nerdymedzebra RT @patientchat: Join us in a few minutes for the Empowered #patientchat. Info/Topics: Join us in a few minutes for the Empowered #patientchat. Info/Topics: https://t.co/lRhU0PEGMz #patientchat |
| Richard Kreis @kreisr1 RT @BarbyIngle: I am @BarbyIngle. I am an ambassador for #cureclick and #HeroLinx clinical trial coordinators to help raise awareness about current trials being conducted for #ChronicPain diseases. #patientchat https://t.co/lOsTx3uq8V |
 | Jack Aiello @JackMAiello Jack joining, active patient advocate but can only stay on 1/2 hour due to Stanford mtg about the same topic #patientchat |
| Richard Kreis @kreisr1 RT @patientchat: Please continue intros and welcomes. I’ll share a couple “ground rules" :) #patientchat |
| Richard Kreis @kreisr1 RT @abrewi3010: Alan here. I’m a #rheum #chronicpain #mentalhealth patient who has a #photography habit as part of my story. #patientchat https://t.co/Ega80UzF2H |
| Patient Chat @patientchat You can view our Chat Etiquette & Guidelines, along with past chat transcripts, at https://t.co/9m9nTL83Mi #patientchat |
| Science 37 @Science37x Hi #patientchat! We are https://t.co/4x77sdTJUP! What a great topic today! Looking forward to the conversation! |
 | Vera Rulon FAHIMA @vrulon Vera here from New York. Have worked in pharma, provider, payer, now have my own business #patientchat |
| Richard Kreis @kreisr1 RT @Science37x: Hi #patientchat! We are https://t.co/4x77sdTJUP! What a great topic today! Looking forward to the conversation! |
| Richard Kreis @kreisr1 RT @patientchat: I’m Kara from @power4patients and I’m excited to be moderating today’s #patientchat on #ClinicalTrials |
| Richard Kreis @kreisr1 RT @H_SalemOaks: Hi #patientchat. Joining from Ann Arbor(-ish) representing @SalemOaks. |
 | Geeky Fox @TechKitsune Geeky Fox here, I'm a Healthcare IT marketing nerd.#patientchat |
| Richard Kreis @kreisr1 RT @JackMAiello: Jack joining, active patient advocate but can only stay on 1/2 hour due to Stanford mtg about the same topic #patientchat |
| Richard Kreis @kreisr1 RT @GoKareo: Hello #PatientChat @GoKareo stopping by the chat today |
| Richard Kreis @kreisr1 RT @patientchat: Join us in a few minutes for the Empowered #patientchat. Info/Topics: Join us in a few minutes for the Empowered #patientchat. Info/Topics: https://t.co/lRhU0PEGMz #patientchat |
| Patient Chat @patientchat Today's #patientchat topic is Overcoming Disparity in Clinical Trials |
| Richard Kreis @kreisr1 RT @not_defeated: I'm looking forward to my first #patientchat |
| Richard Kreis @kreisr1 RT @patientchat: Learn more about the Empowered #patientchat series and how to participate here: Learn more about the Empowered #patientchat series and how to participate here: https://t.co/9m9nTL83Mi |
| Richard Kreis @kreisr1 RT @power4patients: Gotta run and get ready for #patientchat, thank you for a great #HITsm chat @HealthcareScene |
| Richard Kreis @kreisr1 RT @patientchat: Here’s some handy articles on participating in tweet chats: Here’s some handy articles on participating in tweet chats: 1) https://t.co/KMfOQkYb9y and 2) https://t.co/hTxvLlyETu #patientchat |
| Richard Kreis @kreisr1 RT @patientchat: You can view our Chat Etiquette & Guidelines, along with past chat transcripts, at https://t.co/9m9nTL83Mi #patientchat |
| Richard Kreis @kreisr1 RT @patientchat: New to tweet chats? Follow hashtag #patientchat and include it in every tweet during the next hr. You can engage w/others on the topic. |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey @vrulon HEY GIRLFRIEND! #patientchat |
 | Patient Empowerment Network @power4patients RT @patientchat: Today's #patientchat topic is Overcoming Disparity in Clinical Trials |
| Richard Kreis @kreisr1 RT @patientchat: Welcome to #patientchat - where patients, care partners, and advocates come to learn from each other and discuss topics of interest |
| Alan Brewington @abrewi3010 RT @patientchat: Today's #patientchat topic is Overcoming Disparity in Clinical Trials |
| Richard Kreis @kreisr1 RT @patientchat: We start out with introductions - Those joining in, please take a moment to introduce yourself. #patientchat |
| Science 37 @Science37x RT @patientchat: Today's #patientchat topic is Overcoming Disparity in Clinical Trials |
 | Christina Lizaso @btrfly12 RT @patientchat: Welcome to #patientchat - where patients, care partners, and advocates come to learn from each other and discuss topics of interest |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey @Science37x HI THERE!! #patientchat |
| Christina Lizaso @btrfly12 RT @patientchat: New to tweet chats? Follow hashtag #patientchat and include it in every tweet during the next hr. You can engage w/others on the topic. |
| Patient Chat @patientchat Today’s chat by the upcoming Clinical Trial Awareness Week (#CTAW2018) from April 30 - May 4, 2018 #patientchat |
| Richard Kreis @kreisr1 RT @patientchat: Today's #patientchat topic is Overcoming Disparity in Clinical Trials |
| Tebra @TebraOfficial RT @patientchat: You can view our Chat Etiquette & Guidelines, along with past chat transcripts, at https://t.co/9m9nTL83Mi #patientchat |
| Richard Kreis @kreisr1 RT @patientchat: Today’s chat by the upcoming Clinical Trial Awareness Week (#CTAW2018) from April 30 - May 4, 2018 #patientchat |
| Science 37 @Science37x @MightyCasey Hi there! And, hi @not_defeated #patientchat |
 | Marcela Musgrove @marcela Stopping in to say hi from Massachusetts but I know nothing about clinical trials. #patientchat |
| Patient Chat @patientchat Time to start our topics. Here comes T1: https://t.co/lRhU0PEGMz #patientchat |
| Richard Kreis @kreisr1 RT @patientchat: Time to start our topics. Here comes T1: Time to start our topics. Here comes T1: https://t.co/lRhU0PEGMz #patientchat |
| Vera Rulon FAHIMA @vrulon @MightyCasey Back at 'ya!! #patientchat |
| Patient Chat @patientchat T1: Why do you think there is so much disparity in enrollment of minority patient populations in clinical trials? #patientchat |
| Dr. Phyllisa Deroze @not_defeated I'm Phyllisa. Living with T2 diabetes for 7 years. Glad to meet you all. #patientchat |
| Richard Kreis @kreisr1 RT @patientchat: T1: T1: Why do you think there is so much disparity in enrollment of minority patient populations in clinical trials? #patientchat |
| Patient Empowerment Network @power4patients RT @patientchat: T1: T1: Why do you think there is so much disparity in enrollment of minority patient populations in clinical trials? #patientchat |
| Richard Kreis @kreisr1 RT @Crohnoid: |
| Barby Ingle Official @BarbyIngle A1: Theres mistrust when it comes 2 PTs who have been underserved & underTX'ed, there is also a disparity n recruitment of minority PTs. I think because of a lack of access 2 proper/timely care & lack of transparency in past, its harder 4 new trials 2 recruit #patientchat https://t.co/M8qcepNxgv |
 | Inspire @InspireIsHealth Hello, #patientchat, and Happy Friday. John Novack checking in from Inspire. |
| Science 37 @Science37x We do realize we went a little overboard with our punctuation, but we are happy to be able to join today's #patientchat and see two of our great Clinical Research Advocates @MightyCasey and @not_defeated |
| Science 37 @Science37x RT @patientchat: T1: T1: Why do you think there is so much disparity in enrollment of minority patient populations in clinical trials? #patientchat |
| Science 37 @Science37x T1. It’s all about history. Minority patient populations were long mistreated and ignored by science. This timely post from @statnews sheds some light: https://t.co/EBqUMrL46O #patientchat |
| Geeky Fox @TechKitsune A1: As a minority in race and sexual orientation, don't ask don't tell is very real within these communities. You don't talk about problems and rarely ask for solutions. #patientchat https://t.co/2vDVMMYIAg |
| Patient Chat @patientchat RT @BarbyIngle: A1: A1: Theres mistrust when it comes 2 PTs who have been underserved & underTX'ed, there is also a disparity n recruitment of minority PTs. I think because of a lack of access 2 proper/timely care & lack of transparency in past, its harder 4 new trials 2 recruit #patientchat https://t.co/M8qcepNxgv |
| Richard Kreis @kreisr1 RT @MightyCasey: @Science37x HI THERE!! #patientchat |
| Richard Kreis @kreisr1 RT @Science37x: We do realize we went a little overboard with our punctuation, but we are happy to be able to join today's #patientchat and see two of our great Clinical Research Advocates @MightyCasey and @not_defeated |
| Alan Brewington @abrewi3010 A1 access to clinical trial information. Need access to SoMe, docs, hospitals, universities. #patientchat |
| Science 37 @Science37x #patientchat https://t.co/pxigOWP1Kp |
| Richard Kreis @kreisr1 RT @teaminspire: Hello, #patientchat, and Happy Friday. John Novack checking in from Inspire. |
| Nerdy Zebra @nerdymedzebra A1: I would say a combination of pulling heavily from university populations for many types of studies, and the horrific history of experimentation on POC that understandably make them not-eager to volunteer for such things... #patientchat |
 | Lieutenant O'Purra @HealSuffering Good morning from Central California. I am Cheryl and a Mental Health Advocate #patientchat https://t.co/UqdZl2ar3Q |
| Richard Kreis @kreisr1 RT @BarbyIngle: A1: A1: Theres mistrust when it comes 2 PTs who have been underserved & underTX'ed, there is also a disparity n recruitment of minority PTs. I think because of a lack of access 2 proper/timely care & lack of transparency in past, its harder 4 new trials 2 recruit #patientchat https://t.co/M8qcepNxgv |
| Vera Rulon FAHIMA @vrulon @patientchat A1: A couple of reasons - 1) there is a trust issue post Tuskegee, 2) there is a lack of communication and information shared with certain populations (biases, whether conscious or unconscious), 3) the value proposition is not clear #patientchat |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey @Science37x @not_defeated Hey, EVERYONE HERE is excited about #clinicalresearch, so ... you fit right in 😜😜 #patientchat |
| Science 37 @Science37x RT @TechKitsune: A1: A1: As a minority in race and sexual orientation, don't ask don't tell is very real within these communities. You don't talk about problems and rarely ask for solutions. #patientchat https://t.co/2vDVMMYIAg |
| Richard Kreis @kreisr1 RT @TechKitsune: Geeky Fox here, I'm a Healthcare IT marketing nerd.#patientchat |
| Richard Kreis @kreisr1 RT @marcela: Stopping in to say hi from Massachusetts but I know nothing about clinical trials. #patientchat |
| Christina Lizaso @btrfly12 RT @patientchat: T1: T1: Why do you think there is so much disparity in enrollment of minority patient populations in clinical trials? #patientchat |
| Science 37 @Science37x T1. Our own @mightycasey recently wrote a 2-part series about trust in research/science and Henrietta Lacks. In Part 1 she tells the story of Ms Lacks and the #HeLa cells https://t.co/4wBR8aVtLn #patientchat |
| Science 37 @Science37x T1. and in part 2, @mightycasey interviews Henrietta Lacks’ grandson, David Lacks, Jr.: https://t.co/rkYP6bvIo2 #patientchat |
 | iPain Foundation Research Projects @iPain_Research RT @BarbyIngle: A1: A1: Theres mistrust when it comes 2 PTs who have been underserved & underTX'ed, there is also a disparity n recruitment of minority PTs. I think because of a lack of access 2 proper/timely care & lack of transparency in past, its harder 4 new trials 2 recruit #patientchat https://t.co/M8qcepNxgv |
| Science 37 @Science37x RT @MightyCasey: @Science37x @not_defeated Hey, EVERYONE HERE is excited about #clinicalresearch, so ... you fit right in 😜😜 #patientchat |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey this is a critical perspective - must be recognized, and part of our constant work for change. #patientchat https://t.co/4q2YWGU0nC |
| Richard Kreis @kreisr1 RT @abrewi3010: A1 access to clinical trial information. Need access to SoMe, docs, hospitals, universities. #patientchat |
| Science 37 @Science37x RT @vrulon: @patientchat A1: @patientchat A1: A couple of reasons - 1) there is a trust issue post Tuskegee, 2) there is a lack of communication and information shared with certain populations (biases, whether conscious or unconscious), 3) the value proposition is not clear #patientchat |
| Alan Brewington @abrewi3010 A1 paternalistic medicine. To often the standard to compare too is a white male. #patientchat |
| Heather McCullen @H_SalemOaks T1: (Justified?) Distrust as a direct result of the history of medical testing. But also the same reason any person doesn't enroll in clinical trials. No one asked them. #patientchat |
| Science 37 @Science37x @vrulon @patientchat Well said! #patientchat |
| Jack Aiello @JackMAiello A1: Awareness, mistrust, Access/location are among numerous reasons #patientchat |
| Vera Rulon FAHIMA @vrulon @Science37x @statnews Read that article. Raises serious ethical issues related to these populations. #patientchat |
 | Ken Taylor, RPIC @KenRayTaylor RT @BarbyIngle: A1: A1: Theres mistrust when it comes 2 PTs who have been underserved & underTX'ed, there is also a disparity n recruitment of minority PTs. I think because of a lack of access 2 proper/timely care & lack of transparency in past, its harder 4 new trials 2 recruit #patientchat https://t.co/M8qcepNxgv |
| Christina Lizaso @btrfly12 RT @H_SalemOaks: T1: T1: (Justified?) Distrust as a direct result of the history of medical testing. But also the same reason any person doesn't enroll in clinical trials. No one asked them. #patientchat |
| Christina Lizaso @btrfly12 RT @Science37x: T1. Our own @mightycasey recently wrote a 2-part series about trust in research/science and Henrietta Lacks. In Part 1 she tells the story of Ms Lacks and the #HeLa cells https://t.co/4wBR8aVtLn #patientchat |
 | International Pain Foundation® @iPainOfficial RT @BarbyIngle: A1: A1: Theres mistrust when it comes 2 PTs who have been underserved & underTX'ed, there is also a disparity n recruitment of minority PTs. I think because of a lack of access 2 proper/timely care & lack of transparency in past, its harder 4 new trials 2 recruit #patientchat https://t.co/M8qcepNxgv |
| Science 37 @Science37x RT @MightyCasey: this is a critical perspective - must be recognized, and part of our constant work for change. #patientchat https://t.co/4q2YWGU0nC |
| Science 37 @Science37x RT @abrewi3010: A1 paternalistic medicine. To often the standard to compare too is a white male. #patientchat |
 | Lore Noren @see1lorenoren RT @TechKitsune: Geeky Fox here, I'm a Healthcare IT marketing nerd.#patientchat |
| Vera Rulon FAHIMA @vrulon @H_SalemOaks Exactly. And often doctors/providers don't have enough information to share. #patientchat |
| Science 37 @Science37x RT @H_SalemOaks: T1: T1: (Justified?) Distrust as a direct result of the history of medical testing. But also the same reason any person doesn't enroll in clinical trials. No one asked them. #patientchat |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey I'm simultaneously on a prep call for an RWJF/AcademyHealth event next week, so I'll be in'n'out ... #patientchat |
| Science 37 @Science37x RT @vrulon: @Science37x @statnews Read that article. Raises serious ethical issues related to these populations. #patientchat |
| Science 37 @Science37x RT @vrulon: @H_SalemOaks Exactly. And often doctors/providers don't have enough information to share. #patientchat |
| Patient Empowerment Network @power4patients T1: Agree with @abrewi3010 that it's an access issue. Couple that with the mistrust that @BarbyIngle mentions and you have a recipe for disparity. #patientchat |
| Science 37 @Science37x RT @JackMAiello: A1: A1: Awareness, mistrust, Access/location are among numerous reasons #patientchat |
| Science 37 @Science37x T1. Here’s an example: #diabetes is 2x more prevalent in Mexican-American and Puerto Rican communities vs whites, yet those groups only represent 4 percent of diabetes trial participants. https://t.co/nQRIFsa9nX #science37diabetes #patientchat |
| Patient Chat @patientchat Topic 2 (T2:) coming up...https://t.co/lRhU0PEGMz #patientchat |
| Science 37 @Science37x RT @power4patients: T1: T1: Agree with @abrewi3010 that it's an access issue. Couple that with the mistrust that @BarbyIngle mentions and you have a recipe for disparity. #patientchat |
| Lieutenant O'Purra @HealSuffering A1 I think that it's difficult enough to fill enrollment for clinical trials in the first place. It's much more difficult to get the minorities to trust trials such as these because of their previous experiences and cultural stigma. #patientchat https://t.co/N3u1khlIv8 |
| Science 37 @Science37x T1. Another example: #psoriasis affects all ethnicities, but research shows that certain groups are less likely to see a doctor about it: https://t.co/4vtC4UlCPX #patientchat |
 | Janet Kennedy @GetSocialHealth Good Afternoon! I saw that @ShereesePubHlth @MightyCasey and @GoKareo were here so I thought I'd drop into my first #PatientChat. |
| Ken Taylor, RPIC @KenRayTaylor A1: Make more awareness though advertising. Get the word to the target audience. #patientchat https://t.co/IW2DtDhhL0 |
| Patient Chat @patientchat T2: Why do you think it is important to diversify clinical trials? #patientchat |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 A1: Unfortunately #Clinicaltrial design is not formed with a #patientengagement strategy + people of color feel the brunt of poor design #patientchat https://t.co/toAaexQUbz |
| Richard Kreis @kreisr1 RT @power4patients: T1: T1: Agree with @abrewi3010 that it's an access issue. Couple that with the mistrust that @BarbyIngle mentions and you have a recipe for disparity. #patientchat |
| Barby Ingle Official @BarbyIngle A2: Clinical trials need 2 better mirror PTs who will b the user. Especially on DX that appear diff n minority pops. If we dont develop diverse pool of research pts, health disparities may persist We wont know if med is safe & effective n those that ultimately use it #patientchat https://t.co/zodJXmcHNS |
| Richard Kreis @kreisr1 RT @patientchat: T2: T2: Why do you think it is important to diversify clinical trials? #patientchat |
| Barby Ingle Official @BarbyIngle RT @KenRayTaylor: A1: A1: Make more awareness though advertising. Get the word to the target audience. #patientchat https://t.co/IW2DtDhhL0 |
| Richard Kreis @kreisr1 RT @abrewi3010: A1 paternalistic medicine. To often the standard to compare too is a white male. #patientchat |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @Science37x: T1. It’s all about history. Minority patient populations were long mistreated and ignored by science. This timely post from @statnews sheds some light: https://t.co/EBqUMrL46O #patientchat |
| Patient Empowerment Network @power4patients RT @patientchat: T2: T2: Why do you think it is important to diversify clinical trials? #patientchat |
| Science 37 @Science37x RT @KenRayTaylor: A1: A1: Make more awareness though advertising. Get the word to the target audience. #patientchat https://t.co/IW2DtDhhL0 |
| Science 37 @Science37x RT @patientchat: T2: T2: Why do you think it is important to diversify clinical trials? #patientchat |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @Science37x: T1. Here’s an example: T1. Here’s an example: #diabetes is 2x more prevalent in Mexican-American and Puerto Rican communities vs whites, yet those groups only represent 4 percent of diabetes trial participants. https://t.co/nQRIFsa9nX #science37diabetes #patientchat |
| Patient Empowerment Network @power4patients RT @BarbyIngle: A2: A2: Clinical trials need 2 better mirror PTs who will b the user. Especially on DX that appear diff n minority pops. If we dont develop diverse pool of research pts, health disparities may persist We wont know if med is safe & effective n those that ultimately use it #patientchat https://t.co/zodJXmcHNS |
| International Pain Foundation® @iPainOfficial RT @KenRayTaylor: A1: A1: Make more awareness though advertising. Get the word to the target audience. #patientchat https://t.co/IW2DtDhhL0 |
| International Pain Foundation® @iPainOfficial RT @BarbyIngle: A2: A2: Clinical trials need 2 better mirror PTs who will b the user. Especially on DX that appear diff n minority pops. If we dont develop diverse pool of research pts, health disparities may persist We wont know if med is safe & effective n those that ultimately use it #patientchat https://t.co/zodJXmcHNS |
| Science 37 @Science37x T2. It’s crucial to diversify #clinicaltrials because medications work differently in different populations and individuals. If we only study one kind of person, we are not getting all the relevant data. We are doing science a disservice. #patientchat |
| Science 37 @Science37x RT @BarbyIngle: A2: A2: Clinical trials need 2 better mirror PTs who will b the user. Especially on DX that appear diff n minority pops. If we dont develop diverse pool of research pts, health disparities may persist We wont know if med is safe & effective n those that ultimately use it #patientchat https://t.co/zodJXmcHNS |
| Science 37 @Science37x RT @gratefull080504: A1: A1: Unfortunately #Clinicaltrial design is not formed with a #patientengagement strategy + people of color feel the brunt of poor design #patientchat https://t.co/toAaexQUbz |
| Geeky Fox @TechKitsune A2: Because research isn't a one size fits all. We are all made differently but our common denominator could save us if the research is there. #patientchat |
| Heather McCullen @H_SalemOaks RT @gratefull080504: A1: A1: Unfortunately #Clinicaltrial design is not formed with a #patientengagement strategy + people of color feel the brunt of poor design #patientchat https://t.co/toAaexQUbz |
| Richard Kreis @kreisr1 @patientchat A2: Not Everyone fits into one mold. The more people who participate in trials the more can be helped when a treatment is found. #patientchat |
| Richard Kreis @kreisr1 RT @patientchat: You're invited! Join the "Overcoming Disparity in Clinical Trials" #patientchat today at 1pmET https://t.co/oSsnaW27zp https://t.co/bJTkQ8QlgE |
| Vera Rulon FAHIMA @vrulon A2: Treatments vary in their effectiveness given the unique differences of varied populations. For example, if you don't test a new tx with an elderly population, how do you know it is going to work for them? #patientchat |
 | Heidi Grabenstatter @PatientIntv Hi #patientchat, this is a fantastic topic, I am sorry to be late. |
| Tebra @TebraOfficial All patients are different, but there are unique issues based on #ethnicity. We need diverse patient participation to better understand. #PatientChat |
| Dr. Phyllisa Deroze @not_defeated A2. Because one group, one point of view, one type is never good when you want to create something for the masses #patientchat https://t.co/BzCEfpR1RF |
| Patient Empowerment Network @power4patients RT @Science37x: T2. It’s crucial to diversify #clinicaltrials because medications work differently in different populations and individuals. If we only study one kind of person, we are not getting all the relevant data. We are doing science a disservice. #patientchat |
| Shereese Maynard, MS; MBA 😷 She/Her @ShereeseMayMba T1 The clinical community has a long history of documented mistreatment of minorities. This created an equally long history of distrust. This issue has resulted in the issues we see now, not to be easily mitgated. https://t.co/P0RejxxMMs #patientchat |
| Science 37 @Science37x T2. Again, #diabetes example: No one really knows if the treatments getting tested and approved are equally as effective for communities who haven’t had access to them: https://t.co/nQRIFsa9nX #science37diabetes #patientchat |
| Science 37 @Science37x RT @TechKitsune: A2: A2: Because research isn't a one size fits all. We are all made differently but our common denominator could save us if the research is there. #patientchat |
| Science 37 @Science37x RT @kreisr1: @patientchat A2: @patientchat A2: Not Everyone fits into one mold. The more people who participate in trials the more can be helped when a treatment is found. #patientchat |
| Vera Rulon FAHIMA @vrulon @BarbyIngle That's right. Varies by age, ethnicity, etc. etc. #patientchat |
| Alan Brewington @abrewi3010 A2 publish or parish meant all knowledge was good regardless if it helped a human centered issue. Diversity brings the discovery process back to human centered basis. #patientchat |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 A2: I will respond with another question "Who is the #clinicaltrial designed to serve In #KidneyDisease It is many times #africanamerican + #hispanic populations + these communities have not been engaged #patientchat https://t.co/jZgZW7tAno |
| Richard Kreis @kreisr1 RT @BarbyIngle: A2: A2: Clinical trials need 2 better mirror PTs who will b the user. Especially on DX that appear diff n minority pops. If we dont develop diverse pool of research pts, health disparities may persist We wont know if med is safe & effective n those that ultimately use it #patientchat https://t.co/zodJXmcHNS |
| Shereese Maynard, MS; MBA 😷 She/Her @ShereeseMayMba RT @patientchat: T2: T2: Why do you think it is important to diversify clinical trials? #patientchat |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey @GetSocialHealth @ShereesePubHlth @GoKareo HELLOOOO! and welcome 😎 #patientchat |
| Richard Kreis @kreisr1 RT @Science37x: T2. It’s crucial to diversify #clinicaltrials because medications work differently in different populations and individuals. If we only study one kind of person, we are not getting all the relevant data. We are doing science a disservice. #patientchat |
 | Liz Szabo @LizSzabo RT @patientchat: T1: T1: Why do you think there is so much disparity in enrollment of minority patient populations in clinical trials? #patientchat |
| Patient Empowerment Network @power4patients RT @TechKitsune: A2: A2: Because research isn't a one size fits all. We are all made differently but our common denominator could save us if the research is there. #patientchat |
| Science 37 @Science37x RT @gratefull080504: A2: A2: I will respond with another question "Who is the #clinicaltrial designed to serve In #KidneyDisease It is many times #africanamerican + #hispanic populations + these communities have not been engaged #patientchat https://t.co/jZgZW7tAno |
| Jack Aiello @JackMAiello A2: For myeloma pts, blacks are dx’d 2:1 over whites. Asians at a lower rate. Medically, need to better understand diverse populations to help develop better treatments #patientchat |
| Janet Kennedy @GetSocialHealth It seems a good idea to educate under-served populations about clinical trials to make them aware of opportunities and/or health issues. #PatientChat https://t.co/AQCoeYKoaX |
| Science 37 @Science37x RT @ShereesePubHlth: T1 The clinical community has a long history of documented mistreatment of minorities. This created an equally long history of distrust. This issue has resulted in the issues we see now, not to be easily mitgated. https://t.co/P0RejxxMMs #patientchat |
| Science 37 @Science37x RT @not_defeated: A2. Because one group, one point of view, one type is never good when you want to create something for the masses #patientchat https://t.co/BzCEfpR1RF |
| Science 37 @Science37x RT @vrulon: A2: A2: Treatments vary in their effectiveness given the unique differences of varied populations. For example, if you don't test a new tx with an elderly population, how do you know it is going to work for them? #patientchat |
| Science 37 @Science37x RT @GoKareo: All patients are different, but there are unique issues based on #ethnicity. We need diverse patient participation to better understand. #PatientChat |
 | Mary MACK @MaryOCMack T2 Diversifying is more representative of the population. #patientchat |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @gratefull080504: A2: A2: I will respond with another question "Who is the #clinicaltrial designed to serve In #KidneyDisease It is many times #africanamerican + #hispanic populations + these communities have not been engaged #patientchat https://t.co/jZgZW7tAno |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @Science37x: T2. Again, #diabetes example: T2. Again, #diabetes example: No one really knows if the treatments getting tested and approved are equally as effective for communities who haven’t had access to them: https://t.co/nQRIFsa9nX #science37diabetes #patientchat |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 A2: My professional + personal interest is with #clincialtrials in #kidneydisease. African Americans + Hispanic communities suffer the burden of disease + must be represented in the design strategy #patientchat https://t.co/jZgZW7tAno |
| Ken Taylor, RPIC @KenRayTaylor A2: Most people would like to see the results from someone as close to being the same gene make up to our self. #patientchat https://t.co/xwdhhoYhIW |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @ShereesePubHlth: T1 The clinical community has a long history of documented mistreatment of minorities. This created an equally long history of distrust. This issue has resulted in the issues we see now, not to be easily mitgated. https://t.co/P0RejxxMMs #patientchat |
| International Pain Foundation® @iPainOfficial RT @KenRayTaylor: A2: A2: Most people would like to see the results from someone as close to being the same gene make up to our self. #patientchat https://t.co/xwdhhoYhIW |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @not_defeated: A2. Because one group, one point of view, one type is never good when you want to create something for the masses #patientchat https://t.co/BzCEfpR1RF |
| Science 37 @Science37x RT @JackMAiello: A2: A2: For myeloma pts, blacks are dx’d 2:1 over whites. Asians at a lower rate. Medically, need to better understand diverse populations to help develop better treatments #patientchat |
| Inspire @InspireIsHealth @patientchat From the FDA: "Diversity in Clinical Trial Participation" https://t.co/dt7ctQSVX8 T2 #patientchat |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @vrulon: A2: A2: Treatments vary in their effectiveness given the unique differences of varied populations. For example, if you don't test a new tx with an elderly population, how do you know it is going to work for them? #patientchat |
| Science 37 @Science37x RT @MaryOCMack: T2 Diversifying is more representative of the population. #patientchat |
| Richard Kreis @kreisr1 RT @GetSocialHealth: It seems a good idea to educate under-served populations about clinical trials to make them aware of opportunities and/or health issues. #PatientChat https://t.co/AQCoeYKoaX |
| Christina Lizaso @btrfly12 RT @Science37x: T2. It’s crucial to diversify #clinicaltrials because medications work differently in different populations and individuals. If we only study one kind of person, we are not getting all the relevant data. We are doing science a disservice. #patientchat |
| Shereese Maynard, MS; MBA 😷 She/Her @ShereeseMayMba T2 If clinical trials are to yield useful actionable data, diversity is necessary. #Publichealth initiatives depend on info from diverse groups #patientchat |
| Science 37 @Science37x RT @GetSocialHealth: It seems a good idea to educate under-served populations about clinical trials to make them aware of opportunities and/or health issues. #PatientChat https://t.co/AQCoeYKoaX |
| Vera Rulon FAHIMA @vrulon @gratefull080504 Great point. Same goes for so many other diseases/conditions. Clinical trial participants should reflect the diversity (down to %) of given populations who suffer these diseases. #patientchat |
| Richard Kreis @kreisr1 RT @TechKitsune: A2: A2: Because research isn't a one size fits all. We are all made differently but our common denominator could save us if the research is there. #patientchat |
| Science 37 @Science37x RT @gratefull080504: A2: A2: My professional + personal interest is with #clincialtrials in #kidneydisease. African Americans + Hispanic communities suffer the burden of disease + must be represented in the design strategy #patientchat https://t.co/jZgZW7tAno |
| Barby Ingle Official @BarbyIngle RT @KenRayTaylor: A2: A2: Most people would like to see the results from someone as close to being the same gene make up to our self. #patientchat https://t.co/xwdhhoYhIW |
| Alan Brewington @abrewi3010 A2 all humans are different, it’s time we realized and accepted this. #patientchat |
| Christina Lizaso @btrfly12 RT @HealSuffering: A1 I think that it's difficult enough to fill enrollment for clinical trials in the first place. It's much more difficult to get the minorities to trust trials such as these because of their previous experiences and cultural stigma. #patientchat https://t.co/N3u1khlIv8 |
| Heather McCullen @H_SalemOaks The mission of @SalemOaks is to educate everyone about clinical trials, under-served populations are definitely part of that. #patientchat https://t.co/bskZApOAQT |
| Science 37 @Science37x RT @teaminspire: @patientchat From the FDA: @patientchat From the FDA: "Diversity in Clinical Trial Participation" https://t.co/dt7ctQSVX8 T2 #patientchat |
| Patient Chat @patientchat Topic 3 (T3:) coming up...https://t.co/lRhU0PEGMz #patientchat |
| Science 37 @Science37x RT @ShereesePubHlth: T2 If clinical trials are to yield useful actionable data, diversity is necessary. #Publichealth initiatives depend on info from diverse groups #patientchat |
| Science 37 @Science37x RT @vrulon: @gratefull080504 Great point. Same goes for so many other diseases/conditions. Clinical trial participants should reflect the diversity (down to %) of given populations who suffer these diseases. #patientchat |
| Richard Kreis @kreisr1 RT @patientchat: Topic 3 (T3:) coming up...https://t.co/lRhU0PEGMz #patientchat |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 A2: There need to be honest conversations about the lack of relationships with African American + Hispanic communities. Have to have a relationship first #patientchat https://t.co/1CjTUychyK |
| Richard Kreis @kreisr1 RT @MaryOCMack: T2 Diversifying is more representative of the population. #patientchat |
| Richard Kreis @kreisr1 RT @HealSuffering: A1 I think that it's difficult enough to fill enrollment for clinical trials in the first place. It's much more difficult to get the minorities to trust trials such as these because of their previous experiences and cultural stigma. #patientchat https://t.co/N3u1khlIv8 |
| Science 37 @Science37x Seeing so many great comments today! #patientchat |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 Yes #patientchat https://t.co/AVqAYkwlXp |
| Richard Kreis @kreisr1 RT @GoKareo: All patients are different, but there are unique issues based on #ethnicity. We need diverse patient participation to better understand. #PatientChat |
| Patient Chat @patientchat T3: What are some of the barriers to diversifying clinical trials? #patientchat |
| Christina Lizaso @btrfly12 RT @teaminspire: @patientchat From the FDA: @patientchat From the FDA: "Diversity in Clinical Trial Participation" https://t.co/dt7ctQSVX8 T2 #patientchat |
| iPain Foundation Research Projects @iPain_Research RT @KenRayTaylor: A2: A2: Most people would like to see the results from someone as close to being the same gene make up to our self. #patientchat https://t.co/xwdhhoYhIW |
| Geeky Fox @TechKitsune RT @ShereesePubHlth: T2 If clinical trials are to yield useful actionable data, diversity is necessary. #Publichealth initiatives depend on info from diverse groups #patientchat |
 | Annette McKinnon @anetto T2 Toronto has a very diverse population. It makes no sense to leave so many out. Fairness also plays a part. #patientchat |
| Richard Kreis @kreisr1 RT @gratefull080504: A2: A2: I will respond with another question "Who is the #clinicaltrial designed to serve In #KidneyDisease It is many times #africanamerican + #hispanic populations + these communities have not been engaged #patientchat https://t.co/jZgZW7tAno |
| Science 37 @Science37x RT @H_SalemOaks: The mission of @SalemOaks is to educate everyone about clinical trials, under-served populations are definitely part of that. #patientchat https://t.co/bskZApOAQT |
| iPain Foundation Research Projects @iPain_Research RT @KenRayTaylor: A1: A1: Make more awareness though advertising. Get the word to the target audience. #patientchat https://t.co/IW2DtDhhL0 |
| Science 37 @Science37x RT @patientchat: T3: T3: What are some of the barriers to diversifying clinical trials? #patientchat |
| iPain Foundation Research Projects @iPain_Research RT @BarbyIngle: A2: A2: Clinical trials need 2 better mirror PTs who will b the user. Especially on DX that appear diff n minority pops. If we dont develop diverse pool of research pts, health disparities may persist We wont know if med is safe & effective n those that ultimately use it #patientchat https://t.co/zodJXmcHNS |
| Science 37 @Science37x RT @gratefull080504: A2: A2: There need to be honest conversations about the lack of relationships with African American + Hispanic communities. Have to have a relationship first #patientchat https://t.co/1CjTUychyK |
| Dr. Phyllisa Deroze @not_defeated A1. Reading this book will provide many answers to T1. #patientchat https://t.co/wmVLxWFWkw |
| Science 37 @Science37x @gratefull080504 Agreed! #patientchat |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @gratefull080504: A2: A2: My professional + personal interest is with #clincialtrials in #kidneydisease. African Americans + Hispanic communities suffer the burden of disease + must be represented in the design strategy #patientchat https://t.co/jZgZW7tAno |
| Barby Ingle Official @BarbyIngle A3: Lack of outreach from trial creators 2 minorities, distrust of people n leader positions, lack funds/time According to NIH Blacks =12% of the US pop but only 5% of clinical trial participants & Hispanics =16% of the pop but only 1% of clinical trial participants #patientchat https://t.co/9jgG3QLlzo |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @JackMAiello: A2: A2: For myeloma pts, blacks are dx’d 2:1 over whites. Asians at a lower rate. Medically, need to better understand diverse populations to help develop better treatments #patientchat |
| Nerdy Zebra @nerdymedzebra RT @not_defeated: A1. Reading this book will provide many answers to T1. #patientchat https://t.co/wmVLxWFWkw |
| Alan Brewington @abrewi3010 A3 get patients involved from the very beginning. We speak a diff language that scientists, let’s work together to maximize these communication expertise #patientchat |
| Patient Empowerment Network @power4patients Slightly off topic, but have you noticed how some pharma have started to thank #clinicaltrial participants in ads & @PhRMA Go Boldy campaign is doing the same? Finally these patient pioneers are being recognized! #patientchat |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @not_defeated: A1. Reading this book will provide many answers to T1. #patientchat https://t.co/wmVLxWFWkw |
| Shereese Maynard, MS; MBA 😷 She/Her @ShereeseMayMba RT @not_defeated: A1. Reading this book will provide many answers to T1. #patientchat https://t.co/wmVLxWFWkw |
| Patient Empowerment Network @power4patients RT @patientchat: T3: T3: What are some of the barriers to diversifying clinical trials? #patientchat |
| Richard Kreis @kreisr1 RT @BarbyIngle: A3: A3: Lack of outreach from trial creators 2 minorities, distrust of people n leader positions, lack funds/time According to NIH Blacks =12% of the US pop but only 5% of clinical trial participants & Hispanics =16% of the pop but only 1% of clinical trial participants #patientchat https://t.co/9jgG3QLlzo |
| Richard Kreis @kreisr1 RT @JackMAiello: A2: A2: For myeloma pts, blacks are dx’d 2:1 over whites. Asians at a lower rate. Medically, need to better understand diverse populations to help develop better treatments #patientchat |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 A1: Lack of relationships, one size fits all belief, + poor clinical design This is not limited to people of color but also other communities including whites #patientchat https://t.co/RW7LUcDH9T |
| Richard Kreis @kreisr1 RT @power4patients: Slightly off topic, but have you noticed how some pharma have started to thank #clinicaltrial participants in ads & @PhRMA Go Boldy campaign is doing the same? Finally these patient pioneers are being recognized! #patientchat |
| Science 37 @Science37x T3. One of the biggest barriers is trust on all sides. #patientchat |
| Science 37 @Science37x T3. Another is perhaps, doing the "same-old-same-old" - innovation takes effort, and cultural change does too. #patientchat |
| Shereese Maynard, MS; MBA 😷 She/Her @ShereeseMayMba RT @BarbyIngle: A3: A3: Lack of outreach from trial creators 2 minorities, distrust of people n leader positions, lack funds/time According to NIH Blacks =12% of the US pop but only 5% of clinical trial participants & Hispanics =16% of the pop but only 1% of clinical trial participants #patientchat https://t.co/9jgG3QLlzo |
| Science 37 @Science37x RT @anetto: T2 Toronto has a very diverse population. It makes no sense to leave so many out. Fairness also plays a part. #patientchat |
| Mary MACK @MaryOCMack T3: The population as a whole is not equally informed. #patientchat |
| Dr. Phyllisa Deroze @not_defeated A3. Not understanding the barriers around why some people are resultant to join trials AND not knowing how to address those particular issues. #patientchat https://t.co/9f0vLRoD0N |
| Science 37 @Science37x RT @not_defeated: A1. Reading this book will provide many answers to T1. #patientchat https://t.co/wmVLxWFWkw |
 | Kistein Monkhouse, MPA @KisteinM @patientchat Kistein Monkhouse from @PatientOrator #patientchat |
| Science 37 @Science37x RT @BarbyIngle: A3: A3: Lack of outreach from trial creators 2 minorities, distrust of people n leader positions, lack funds/time According to NIH Blacks =12% of the US pop but only 5% of clinical trial participants & Hispanics =16% of the pop but only 1% of clinical trial participants #patientchat https://t.co/9jgG3QLlzo |
| Tebra @TebraOfficial T3: Barriers - Awareness - Are we educating in #PrimaryCare practices enough about #ClinicalTrials? #PatientChat |
| Science 37 @Science37x RT @abrewi3010: A3 get patients involved from the very beginning. We speak a diff language that scientists, let’s work together to maximize these communication expertise #patientchat |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 A3: Relationships are the foundation to a #patientengagement strategy in #clinicaldesign for all communities #patientchat https://t.co/RW7LUcDH9T |
| Jack Aiello @JackMAiello A3: At the time of CT protocol design, trials include diversity accrual goals. Yet, there is really a plans to achieve those goals since achieving overall accrual is the greatest concern. #patientchat |
| Science 37 @Science37x RT @gratefull080504: A1: A1: Lack of relationships, one size fits all belief, + poor clinical design This is not limited to people of color but also other communities including whites #patientchat https://t.co/RW7LUcDH9T |
| Patient Empowerment Network @power4patients #patientchat |
| Shereese Maynard, MS; MBA 😷 She/Her @ShereeseMayMba A3 And research grants are rarely given to initiatives that consider minority health and trials. I know; I've done the legwork #patientchat |
| Geeky Fox @TechKitsune A3: Lack of healthcare options face these communities. Therefore lack of understanding or knowledge about clinical trials. Also what I said earlier about not asking and not telling. #patientchat |
| Science 37 @Science37x RT @not_defeated: A3. Not understanding the barriers around why some people are resultant to join trials AND not knowing how to address those particular issues. #patientchat https://t.co/9f0vLRoD0N |
| Geeky Fox @TechKitsune RT @BarbyIngle: A3: A3: Lack of outreach from trial creators 2 minorities, distrust of people n leader positions, lack funds/time According to NIH Blacks =12% of the US pop but only 5% of clinical trial participants & Hispanics =16% of the pop but only 1% of clinical trial participants #patientchat https://t.co/9jgG3QLlzo |
| Vera Rulon FAHIMA @vrulon A3: Add to already mentioned barriers: bureaucratic processes in current trials & lack of automation (but very slowly getting better); and most importantly - not including patients in trial design. Include patients and diversity will improve. #patientchat |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @BarbyIngle: A3: A3: Lack of outreach from trial creators 2 minorities, distrust of people n leader positions, lack funds/time According to NIH Blacks =12% of the US pop but only 5% of clinical trial participants & Hispanics =16% of the pop but only 1% of clinical trial participants #patientchat https://t.co/9jgG3QLlzo |
| Patient Empowerment Network @power4patients RT @JackMAiello: A3: A3: At the time of CT protocol design, trials include diversity accrual goals. Yet, there is really a plans to achieve those goals since achieving overall accrual is the greatest concern. #patientchat |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @ShereesePubHlth: A3 And research grants are rarely given to initiatives that consider minority health and trials. I know; I've done the legwork #patientchat |
| Alan Brewington @abrewi3010 T3 we still have a health literacy issue in our country. Poor healthcare literacy will mean in accurate communication #patientchat |
| Science 37 @Science37x RT @gratefull080504: A3: A3: Relationships are the foundation to a #patientengagement strategy in #clinicaldesign for all communities #patientchat https://t.co/RW7LUcDH9T |
| Jack Aiello @JackMAiello Sorry, meant there is NO plan...#patientchat |
| Heather McCullen @H_SalemOaks T3: Understanding our own position and not assuming we know what will work best for any person or population. Some things that may sound like "answers" are actually extremely condescending and based in preconceptions. #patientchat |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 A3 Great transparency + recognition that relationships are a priority will go a long way in improving clinical trail design #patientchat |
| Heather McCullen @H_SalemOaks RT @abrewi3010: A3 get patients involved from the very beginning. We speak a diff language that scientists, let’s work together to maximize these communication expertise #patientchat |
| Christina Lizaso @btrfly12 Resources | Many FDA and NIH patient outreach resources/toolkits in English and Spanish can be found via this #SaludTues chat last year on minority participation in #clinicaltrials https://t.co/U8UjKvqWSa #patientchat |
| Ken Taylor, RPIC @KenRayTaylor A3: Trust is one of the biggest barriers. People dont want to feel like they are being experimented on. Many times there is no way to get the medication after the study if it did help you. #patientchat https://t.co/DevtpYsRwy |
 | Healthcare Writers @HMNwriters T3: Just getting to basic healthcare is a challenge. Transportation, time away from the job, fear, "what's in it for me?" all present barriers to #clinicaltrials #PatientChat |
| Science 37 @Science37x @gratefull080504 Agreed, and building relationships and trust take time, effort, humility... Sadly, it is easier to do things the way they have always been done. #patientchat |
| Christina Lizaso @btrfly12 RT @ShereesePubHlth: A3 And research grants are rarely given to initiatives that consider minority health and trials. I know; I've done the legwork #patientchat |
| Science 37 @Science37x RT @ShereesePubHlth: A3 And research grants are rarely given to initiatives that consider minority health and trials. I know; I've done the legwork #patientchat |
| Kistein Monkhouse, MPA @KisteinM A1: Often times minority patient population is left out of the conversation for clinical trials. This can be seen in tv commercials, where the minority population is often underrepresented/under-targeted. #patientchat https://t.co/6TD5tKzjjq |
| Science 37 @Science37x RT @TechKitsune: A3: A3: Lack of healthcare options face these communities. Therefore lack of understanding or knowledge about clinical trials. Also what I said earlier about not asking and not telling. #patientchat |
| Patient Chat @patientchat Topic 4 (T4:) coming up...https://t.co/lRhU0PEGMz #patientchat |
| Science 37 @Science37x RT @H_SalemOaks: T3: T3: Understanding our own position and not assuming we know what will work best for any person or population. Some things that may sound like "answers" are actually extremely condescending and based in preconceptions. #patientchat |
| Christina Lizaso @btrfly12 RT @abrewi3010: A3 get patients involved from the very beginning. We speak a diff language that scientists, let’s work together to maximize these communication expertise #patientchat |
| Science 37 @Science37x RT @gratefull080504: A3 Great transparency + recognition that relationships are a priority will go a long way in improving clinical trail design #patientchat |
| Alan Brewington @abrewi3010 T3 the fear of failure even though failure can be an invaluable piece of knowledge #patientchat |
| Science 37 @Science37x RT @btrfly12: Resources | Many FDA and NIH patient outreach resources/toolkits in English and Spanish can be found via this #SaludTues chat last year on minority participation in #clinicaltrials https://t.co/U8UjKvqWSa #patientchat |
| Christina Lizaso @btrfly12 RT @BarbyIngle: A3: A3: Lack of outreach from trial creators 2 minorities, distrust of people n leader positions, lack funds/time According to NIH Blacks =12% of the US pop but only 5% of clinical trial participants & Hispanics =16% of the pop but only 1% of clinical trial participants #patientchat https://t.co/9jgG3QLlzo |
| Science 37 @Science37x RT @KenRayTaylor: A3: A3: Trust is one of the biggest barriers. People dont want to feel like they are being experimented on. Many times there is no way to get the medication after the study if it did help you. #patientchat https://t.co/DevtpYsRwy |
| Barby Ingle Official @BarbyIngle RT @KenRayTaylor: A3: A3: Trust is one of the biggest barriers. People dont want to feel like they are being experimented on. Many times there is no way to get the medication after the study if it did help you. #patientchat https://t.co/DevtpYsRwy |
| Science 37 @Science37x RT @HMNwriters: T3: T3: Just getting to basic healthcare is a challenge. Transportation, time away from the job, fear, "what's in it for me?" all present barriers to #clinicaltrials #PatientChat |
| Christina Lizaso @btrfly12 RT @anetto: T2 Toronto has a very diverse population. It makes no sense to leave so many out. Fairness also plays a part. #patientchat |
| Patient Chat @patientchat T4: How can researchers improve engagement and recruitment of minority patient populations? #patientchat |
| Shereese Maynard, MS; MBA 😷 She/Her @ShereeseMayMba RT @patientchat: T4: T4: How can researchers improve engagement and recruitment of minority patient populations? #patientchat |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 @Science37x : You nailed it Building trust takes times + can't be forced or rushed. You get it!! #patientchat https://t.co/6R0JljyhfA |
| Christina Lizaso @btrfly12 RT @Science37x: @gratefull080504 Agreed, and building relationships and trust take time, effort, humility... Sadly, it is easier to do things the way they have always been done. #patientchat |
| Science 37 @Science37x RT @patientchat: Topic 4 (T4:) coming up...https://t.co/lRhU0PEGMz #patientchat |
| Annette McKinnon @anetto T3. People running #clinicaltrials need to allow more recruitment time to include under represented voices. You can’t just expect this to happen. There are real barriers that can be overcome with good strategies. #patientengagement #patientchat |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey @Science37x @gratefull080504 The dreaded "We've always done it this way" syndrome .... #patientchat |
| Christina Lizaso @btrfly12 RT @HMNwriters: T3: T3: Just getting to basic healthcare is a challenge. Transportation, time away from the job, fear, "what's in it for me?" all present barriers to #clinicaltrials #PatientChat |
| Shereese Maynard, MS; MBA 😷 She/Her @ShereeseMayMba RT @anetto: T3. People running #clinicaltrials need to allow more recruitment time to include under represented voices. You can’t just expect this to happen. There are real barriers that can be overcome with good strategies. #patientengagement #patientchat |
| Tebra @TebraOfficial RT @btrfly12: Resources | Many FDA and NIH patient outreach resources/toolkits in English and Spanish can be found via this #SaludTues chat last year on minority participation in #clinicaltrials https://t.co/U8UjKvqWSa #patientchat |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @Science37x: @gratefull080504 Agreed, and building relationships and trust take time, effort, humility... Sadly, it is easier to do things the way they have always been done. #patientchat |
| Kistein Monkhouse, MPA @KisteinM Q2: It’s important to diversify clinical trials since neglecting segments of the population ultimately affects overall population health outcomes. #patientchat https://t.co/cewx7Bu4qz |
| Ken Taylor, RPIC @KenRayTaylor RT @BarbyIngle: A3: A3: Lack of outreach from trial creators 2 minorities, distrust of people n leader positions, lack funds/time According to NIH Blacks =12% of the US pop but only 5% of clinical trial participants & Hispanics =16% of the pop but only 1% of clinical trial participants #patientchat https://t.co/9jgG3QLlzo |
| Science 37 @Science37x @gratefull080504 We try! Thank you! :) #patientchat |
| Jack Aiello @JackMAiello Sorry but gotta leave this great discussion. Will look at final chat log later. #patientchat |
| Science 37 @Science37x RT @gratefull080504: @Science37x : @Science37x : You nailed it Building trust takes times + can't be forced or rushed. You get it!! #patientchat https://t.co/6R0JljyhfA |
| Science 37 @Science37x RT @MightyCasey: @Science37x @gratefull080504 The dreaded "We've always done it this way" syndrome .... #patientchat |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey @gratefull080504 @Science37x Why I'm working for 'em!! #patientchat |
| Science 37 @Science37x RT @patientchat: T4: T4: How can researchers improve engagement and recruitment of minority patient populations? #patientchat |
| International Pain Foundation® @iPainOfficial RT @KenRayTaylor: A3: A3: Trust is one of the biggest barriers. People dont want to feel like they are being experimented on. Many times there is no way to get the medication after the study if it did help you. #patientchat https://t.co/DevtpYsRwy |
| International Pain Foundation® @iPainOfficial RT @BarbyIngle: A3: A3: Lack of outreach from trial creators 2 minorities, distrust of people n leader positions, lack funds/time According to NIH Blacks =12% of the US pop but only 5% of clinical trial participants & Hispanics =16% of the pop but only 1% of clinical trial participants #patientchat https://t.co/9jgG3QLlzo |
| Science 37 @Science37x RT @abrewi3010: T3 the fear of failure even though failure can be an invaluable piece of knowledge #patientchat |
| Christina Lizaso @btrfly12 RT @vrulon: A3: Add to already mentioned barriers: A3: Add to already mentioned barriers: bureaucratic processes in current trials & lack of automation (but very slowly getting better); and most importantly - not including patients in trial design. Include patients and diversity will improve. #patientchat |
| Patient Empowerment Network @power4patients T3: Overcoming barriers requires open communication on all sides. For patients & caregivers this means health literacy is more essential than ever. Our #ClinicalTrial Mythbusters series aims to help: https://t.co/yaxZVxPeM1 #patientchat |
| Geeky Fox @TechKitsune A4: Give them more information, more outreach can go a long way. Minority communities may be closed off but they are surprisingly some of the most open when a new idea is presented in a way that is understanding, helpful, and transparent. #patientchat |
| Lieutenant O'Purra @HealSuffering Genetic differences among people from underrepresented populations can lead to different responses to certain medications. According to the NMA "someone of African descent may respond to a drug differently than someone of Hispanic or Asian descent" #patientchat https://t.co/wQatOwTqpV |
| Science 37 @Science37x RT @anetto: T3. People running #clinicaltrials need to allow more recruitment time to include under represented voices. You can’t just expect this to happen. There are real barriers that can be overcome with good strategies. #patientengagement #patientchat |
| Vera Rulon FAHIMA @vrulon @KisteinM Great point. Diversity needs to start from the beginning. #patientchat |
| Science 37 @Science37x T4. Abandoning assumptions and embracing listening is so important. #patientchat |
| iPain Foundation Research Projects @iPain_Research RT @BarbyIngle: A3: A3: Lack of outreach from trial creators 2 minorities, distrust of people n leader positions, lack funds/time According to NIH Blacks =12% of the US pop but only 5% of clinical trial participants & Hispanics =16% of the pop but only 1% of clinical trial participants #patientchat https://t.co/9jgG3QLlzo |
| iPain Foundation Research Projects @iPain_Research RT @KenRayTaylor: A3: A3: Trust is one of the biggest barriers. People dont want to feel like they are being experimented on. Many times there is no way to get the medication after the study if it did help you. #patientchat https://t.co/DevtpYsRwy |
| Christina Lizaso @btrfly12 RT @anetto: T3. People running #clinicaltrials need to allow more recruitment time to include under represented voices. You can’t just expect this to happen. There are real barriers that can be overcome with good strategies. #patientengagement #patientchat |
| Science 37 @Science37x RT @power4patients: T3: T3: Overcoming barriers requires open communication on all sides. For patients & caregivers this means health literacy is more essential than ever. Our #ClinicalTrial Mythbusters series aims to help: https://t.co/yaxZVxPeM1 #patientchat |
| Science 37 @Science37x RT @MightyCasey: @gratefull080504 @Science37x Why I'm working for 'em!! #patientchat |
| Alan Brewington @abrewi3010 A4 Ask “how might we...” instead of “you must do...” #patientchat |
| Janet Kennedy @GetSocialHealth RT @power4patients: T3: T3: Overcoming barriers requires open communication on all sides. For patients & caregivers this means health literacy is more essential than ever. Our #ClinicalTrial Mythbusters series aims to help: https://t.co/yaxZVxPeM1 #patientchat |
| Kistein Monkhouse, MPA @KisteinM A3: barriers to diversifying clinical trials can be locations I.e reaching those living in rural areas. #patientchat https://t.co/D2Ny4C6tPd |
| Healthcare Writers @HMNwriters RT @BarbyIngle: A3: A3: Lack of outreach from trial creators 2 minorities, distrust of people n leader positions, lack funds/time According to NIH Blacks =12% of the US pop but only 5% of clinical trial participants & Hispanics =16% of the pop but only 1% of clinical trial participants #patientchat https://t.co/9jgG3QLlzo |
| Science 37 @Science37x @MightyCasey @gratefull080504 And it's why we love having you! #patientchat |
| Vera Rulon FAHIMA @vrulon @MightyCasey @Science37x @gratefull080504 Absolutely. Was a great cause of angst trying to implement an automated trials system... #patientchat |
| Patient Empowerment Network @power4patients RT @patientchat: T4: T4: How can researchers improve engagement and recruitment of minority patient populations? #patientchat |
| Science 37 @Science37x RT @TechKitsune: A4: A4: Give them more information, more outreach can go a long way. Minority communities may be closed off but they are surprisingly some of the most open when a new idea is presented in a way that is understanding, helpful, and transparent. #patientchat |
| Barby Ingle Official @BarbyIngle A4: Improvements can come from collected data on # of people at zip codes had particular DX and who treated them. Clinical Trial coordinators could use this data to help facilitate trial recruitment & engage minority providers to help raise awareness as well #patientchat https://t.co/Uwp0WTNaI9 |
| Science 37 @Science37x RT @HealSuffering: Genetic differences among people from underrepresented populations can lead to different responses to certain medications. According to the NMA "someone of African descent may respond to a drug differently than someone of Hispanic or Asian descent" #patientchat https://t.co/wQatOwTqpV |
| Christina Lizaso @btrfly12 RT @TechKitsune: A4: A4: Give them more information, more outreach can go a long way. Minority communities may be closed off but they are surprisingly some of the most open when a new idea is presented in a way that is understanding, helpful, and transparent. #patientchat |
| Geeky Fox @TechKitsune RT @Science37x: T4. Abandoning assumptions and embracing listening is so important. #patientchat |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 A4: This is not really that difficult Make a commitment to developing long term relationships with patient communities Humility is required. Check your ego at the door + be willing to listen + learn #patientchat https://t.co/h1zXVbgyTR |
| Vera Rulon FAHIMA @vrulon A4: Here's an example where a pediatric population was included and diversity in age improved. Perhaps an approach for minorities? #patientchat https://t.co/1TbHUJnVdx |
 | Amanda G @LAlupusLady Reach out to people in the community, churches and schools. #patientchat https://t.co/qkJZjfkUIa |
| Patient Chat @patientchat @JackMAiello Thanks for stopping by Jack! Have a great weekend #patientchat |
| Christina Lizaso @btrfly12 RT @BarbyIngle: A4: A4: Improvements can come from collected data on # of people at zip codes had particular DX and who treated them. Clinical Trial coordinators could use this data to help facilitate trial recruitment & engage minority providers to help raise awareness as well #patientchat https://t.co/Uwp0WTNaI9 |
| Janet Kennedy @GetSocialHealth Get in the social media game, people! Minorities are well represented in Social Media so start sharing your messages! #PatientChat https://t.co/OEvczcXNn2 |
| Christina Lizaso @btrfly12 RT @abrewi3010: A4 Ask “how might we...” instead of “you must do...” #patientchat |
| Christina Lizaso @btrfly12 RT @GetSocialHealth: Get in the social media game, people! Minorities are well represented in Social Media so start sharing your messages! #PatientChat https://t.co/OEvczcXNn2 |
| Christina Lizaso @btrfly12 RT @LAlupusLady: Reach out to people in the community, churches and schools. #patientchat https://t.co/qkJZjfkUIa |
| Mary MACK @MaryOCMack T4: Make sure every community's primary care docs and clinics are informed of clinical trials recruiting. #patientchat |
| Alan Brewington @abrewi3010 T4 go old school, LISTEN! #patientchat |
| Heather McCullen @H_SalemOaks RT @abrewi3010: A4 Ask “how might we...” instead of “you must do...” #patientchat |
| Science 37 @Science37x RT @KisteinM: A3: A3: barriers to diversifying clinical trials can be locations I.e reaching those living in rural areas. #patientchat https://t.co/D2Ny4C6tPd |
| Vera Rulon FAHIMA @vrulon @LAlupusLady For sure. That's where people hold great #trust and can help #patientchat |
| Kistein Monkhouse, MPA @KisteinM A3: cultural competency is a huge barrier in clinical trials. I.e are you meeting patients at their levels, is staff/recruiters speaking the language, comprehends the make disparities that vulnerable populations face, etc.. #patientchat https://t.co/D2Ny4C6tPd |
| Amanda G @LAlupusLady RT @vrulon: @LAlupusLady For sure. That's where people hold great #trust and can help #patientchat |
| Science 37 @Science37x @KisteinM Yes! That is one of the things we are working to revolutionize here at https://t.co/HzX7BzdX4V #patientchat |
| Dr. Phyllisa Deroze @not_defeated A4. Try first to understand the culture. For example, Religious people in the South aren't going to participate in anything that inferers w/ Sunday service & Bible Study. #patientchat https://t.co/rvd3NzejT4 |
| Science 37 @Science37x RT @gratefull080504: A4: A4: This is not really that difficult Make a commitment to developing long term relationships with patient communities Humility is required. Check your ego at the door + be willing to listen + learn #patientchat https://t.co/h1zXVbgyTR |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 A4 The @FDA + @ASN formed the Kidney Health Initiate to address the lack of innovation in #kidneydisease @ASNKidney is committed to developing a #patietnvoice strategy #patientchat |
| Science 37 @Science37x RT @vrulon: A4: A4: Here's an example where a pediatric population was included and diversity in age improved. Perhaps an approach for minorities? #patientchat https://t.co/1TbHUJnVdx |
| Ken Taylor, RPIC @KenRayTaylor A4: Create interactive recruitment tools that make people want to participate and target the population your after. #patientchat https://t.co/Ug8KUE9wF3 |
| Science 37 @Science37x RT @LAlupusLady: Reach out to people in the community, churches and schools. #patientchat https://t.co/qkJZjfkUIa |
| Vera Rulon FAHIMA @vrulon @GetSocialHealth Ha ha! In the past researchers were mortified that clinical trial participants were discussing their clinical trials on SoMe... so much for blinded studies!! #patientchat |
| Science 37 @Science37x RT @GetSocialHealth: Get in the social media game, people! Minorities are well represented in Social Media so start sharing your messages! #PatientChat https://t.co/OEvczcXNn2 |
| Science 37 @Science37x RT @MaryOCMack: T4: T4: Make sure every community's primary care docs and clinics are informed of clinical trials recruiting. #patientchat |
| Shereese Maynard, MS; MBA 😷 She/Her @ShereeseMayMba @KisteinM This is a huge problem . Many clinical trial teams have no buy-in to underserved communities and there's no attempt to include person who do have that buy-in. #patientchat |
 | Katie @katie5280 @patientchat T1: Agreed! It can be challenging to find information on current trials. #patientchat |
| Barby Ingle Official @BarbyIngle RT @KenRayTaylor: A4: A4: Create interactive recruitment tools that make people want to participate and target the population your after. #patientchat https://t.co/Ug8KUE9wF3 |
| Heidi Grabenstatter @PatientIntv T4: Patient portals should prompt individuals when relevant trials become available. Extend reach beyond University to rural and urban hospitals with consistent, standardized platforms. Also notify at appt. #patientchat https://t.co/Tckv95D3Y1 |
| Patient Chat @patientchat Topic 5 (T5:) coming up...https://t.co/lRhU0PEGMz #patientchat |
| Inspire @InspireIsHealth @LAlupusLady T4 We second that. We see some successful efforts among our nonprofit partners in connecting to patients/caregivers via civic and church groups. Connecting on their turf seems to increase hard-to-gain trust. #patientchat |
| Science 37 @Science37x RT @KisteinM: A3: A3: cultural competency is a huge barrier in clinical trials. I.e are you meeting patients at their levels, is staff/recruiters speaking the language, comprehends the make disparities that vulnerable populations face, etc.. #patientchat https://t.co/D2Ny4C6tPd |
| Janet Kennedy @GetSocialHealth How about Health Information Stations in Public Libraries? Screen with website links, and info that can be emailed home or printed to take to the physician? #PatientChat |
| Vera Rulon FAHIMA @vrulon @not_defeated Excellent point. #culture is paramount to understanding what makes a group tick and further helps get the message across. #patientchat |
| Science 37 @Science37x RT @not_defeated: A4. Try first to understand the culture. For example, Religious people in the South aren't going to participate in anything that inferers w/ Sunday service & Bible Study. #patientchat https://t.co/rvd3NzejT4 |
| Amanda G @LAlupusLady RT @teaminspire: @LAlupusLady T4 We second that. We see some successful efforts among our nonprofit partners in connecting to patients/caregivers via civic and church groups. Connecting on their turf seems to increase hard-to-gain trust. #patientchat |
| Patient Chat @patientchat T5: How will those tactics be used across different ages, races and genders? #patientchat |
| Shereese Maynard, MS; MBA 😷 She/Her @ShereeseMayMba @katie5280 @patientchat Yeah, https://t.co/zBNNACQC0A needs a serious overhaul #patientchat |
| Science 37 @Science37x RT @gratefull080504: A4 The @FDA + @ASN formed the Kidney Health Initiate to address the lack of innovation in #kidneydisease @ASNKidney is committed to developing a #patietnvoice strategy #patientchat |
| Science 37 @Science37x RT @KenRayTaylor: A4: A4: Create interactive recruitment tools that make people want to participate and target the population your after. #patientchat https://t.co/Ug8KUE9wF3 |
| Christina Lizaso @btrfly12 RT @gratefull080504: A4 The @FDA + @ASN formed the Kidney Health Initiate to address the lack of innovation in #kidneydisease @ASNKidney is committed to developing a #patietnvoice strategy #patientchat |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @ShereesePubHlth: @KisteinM This is a huge problem . Many clinical trial teams have no buy-in to underserved communities and there's no attempt to include person who do have that buy-in. #patientchat |
| iPain Foundation Research Projects @iPain_Research RT @KenRayTaylor: A4: A4: Create interactive recruitment tools that make people want to participate and target the population your after. #patientchat https://t.co/Ug8KUE9wF3 |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 @ShereesePubHlth : The @ASNKidney is committed to changing this dynamic #patientchat https://t.co/BsfJ8MutEa |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @power4patients: T3: T3: Overcoming barriers requires open communication on all sides. For patients & caregivers this means health literacy is more essential than ever. Our #ClinicalTrial Mythbusters series aims to help: https://t.co/yaxZVxPeM1 #patientchat |
| Science 37 @Science37x RT @vrulon: @GetSocialHealth Ha ha! In the past researchers were mortified that clinical trial participants were discussing their clinical trials on SoMe... so much for blinded studies!! #patientchat |
| iPain Foundation Research Projects @iPain_Research RT @BarbyIngle: A4: A4: Improvements can come from collected data on # of people at zip codes had particular DX and who treated them. Clinical Trial coordinators could use this data to help facilitate trial recruitment & engage minority providers to help raise awareness as well #patientchat https://t.co/Uwp0WTNaI9 |
| Shereese Maynard, MS; MBA 😷 She/Her @ShereeseMayMba RT @gratefull080504: @ShereesePubHlth : @ShereesePubHlth : The @ASNKidney is committed to changing this dynamic #patientchat https://t.co/BsfJ8MutEa |
| Science 37 @Science37x RT @ShereesePubHlth: @KisteinM This is a huge problem . Many clinical trial teams have no buy-in to underserved communities and there's no attempt to include person who do have that buy-in. #patientchat |
| Science 37 @Science37x RT @PatientIntv: T4: T4: Patient portals should prompt individuals when relevant trials become available. Extend reach beyond University to rural and urban hospitals with consistent, standardized platforms. Also notify at appt. #patientchat https://t.co/Tckv95D3Y1 |
| Christina Lizaso @btrfly12 RT @MaryOCMack: T4: T4: Make sure every community's primary care docs and clinics are informed of clinical trials recruiting. #patientchat |
| International Pain Foundation® @iPainOfficial RT @BarbyIngle: A4: A4: Improvements can come from collected data on # of people at zip codes had particular DX and who treated them. Clinical Trial coordinators could use this data to help facilitate trial recruitment & engage minority providers to help raise awareness as well #patientchat https://t.co/Uwp0WTNaI9 |
| Science 37 @Science37x RT @teaminspire: @LAlupusLady T4 We second that. We see some successful efforts among our nonprofit partners in connecting to patients/caregivers via civic and church groups. Connecting on their turf seems to increase hard-to-gain trust. #patientchat |
| International Pain Foundation® @iPainOfficial RT @KenRayTaylor: A4: A4: Create interactive recruitment tools that make people want to participate and target the population your after. #patientchat https://t.co/Ug8KUE9wF3 |
| Science 37 @Science37x RT @GetSocialHealth: How about Health Information Stations in Public Libraries? Screen with website links, and info that can be emailed home or printed to take to the physician? #PatientChat |
| Ken Taylor, RPIC @KenRayTaylor RT @BarbyIngle: A4: A4: Improvements can come from collected data on # of people at zip codes had particular DX and who treated them. Clinical Trial coordinators could use this data to help facilitate trial recruitment & engage minority providers to help raise awareness as well #patientchat https://t.co/Uwp0WTNaI9 |
| Christina Lizaso @btrfly12 RT @PatientIntv: T4: T4: Patient portals should prompt individuals when relevant trials become available. Extend reach beyond University to rural and urban hospitals with consistent, standardized platforms. Also notify at appt. #patientchat https://t.co/Tckv95D3Y1 |
| Science 37 @Science37x RT @vrulon: @not_defeated Excellent point. #culture is paramount to understanding what makes a group tick and further helps get the message across. #patientchat |
| Science 37 @Science37x RT @patientchat: T5: T5: How will those tactics be used across different ages, races and genders? #patientchat |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey Truer words were never spoken! It's like spelunking in a dark cave, that site. Or Where's-Waldo, but Waldo's missing. #patientchat https://t.co/MvXCSxzX1Z |
| Alan Brewington @abrewi3010 T5 active listening, active communication, asking how might we doesn’t care about gender, minority status, race, etc. it only cares about human centered solutions #patientchat |
| Science 37 @Science37x T5. When you abandon assumptions & embrace listening, you open yourself up to learning from different people/populations. Ask THEM what’s important to them, to better serve them. #patientchat |
| Barby Ingle Official @BarbyIngle A5: The data of the people who are tracked for specific conditions can be used in recruitment, marketing to those PTs specifically, and developing treatment options through trials that help the actual PT population at greatest risk for disease complications #patientchat https://t.co/afeE6nGmi3 |
 | Alicia C. Staley @stales RT @Science37x: T1. Here’s an example: T1. Here’s an example: #diabetes is 2x more prevalent in Mexican-American and Puerto Rican communities vs whites, yet those groups only represent 4 percent of diabetes trial participants. https://t.co/nQRIFsa9nX #science37diabetes #patientchat |
| Heather McCullen @H_SalemOaks RT @abrewi3010: T5 active listening, active communication, asking how might we doesn’t care about gender, minority status, race, etc. it only cares about human centered solutions #patientchat |
| Patient Empowerment Network @power4patients T4: Diversity is critically important but we have to keep in mind that overall < 5% of eligible patients participate in #clinicaltrials. LESS THAN 5%! I think the solution partially lies in telling the stories of "patient pioneers" Here's 1: https://t.co/piF4SW3mU4 #patientchat |
| Kistein Monkhouse, MPA @KisteinM A4: Invest more into reaching, engaging and recruiting minority populations. Collaborate with non traditional partners such as community based organizations, as well as minority patient advocacy groups, religious organization,etc. #patientchat https://t.co/iDtn9M2BTP |
| Patient Empowerment Network @power4patients RT @abrewi3010: T5 active listening, active communication, asking how might we doesn’t care about gender, minority status, race, etc. it only cares about human centered solutions #patientchat |
| Annette McKinnon @anetto @Justinrt4444 Yes, and look at representation of minorities among researchers and clinicians as well. We want to see ourselves represented on team. #PatientChat |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @Science37x: T5. When you abandon assumptions & embrace listening, you open yourself up to learning from different people/populations. Ask THEM what’s important to them, to better serve them. #patientchat |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 A5: @patientchat : That is the inherent problem of moving to tactics first without a #patientengagement strategy Strategy first if you want to address root issues not symptoms #patientchat https://t.co/pD7OwwziMu |
| Shereese Maynard, MS; MBA 😷 She/Her @ShereeseMayMba @MightyCasey If memory serves, they're currently operating on 33% of their original budget but I've been contemplating sending them an unsolicited proposal to update it. #patientchat |
| Geeky Fox @TechKitsune A5: At some point everyone has a story and wants to be listened to. Outreach in communities is impactful because it is human interaction with the thought of helping someone who didn't know there were opportunities. #patientchat #HITsm |
| Lieutenant O'Purra @HealSuffering Underrepresented populations in minority and rural communities may not have adequate information to participate in clinical trials. In addition, the lack of info may lead them to believe it would cost them to partake. #patientchat https://t.co/Hm7hRx1xsR |
| Katie @katie5280 @patientchat T4: Specifically market to areas with those populations, especially rural areas. Not everyone uses social media, so sending flyers or info via USPS could be helpful. #patientchat |
| Science 37 @Science37x RT @BarbyIngle: A5: A5: The data of the people who are tracked for specific conditions can be used in recruitment, marketing to those PTs specifically, and developing treatment options through trials that help the actual PT population at greatest risk for disease complications #patientchat https://t.co/afeE6nGmi3 |
| Alicia C. Staley @stales RT @Science37x: T5. When you abandon assumptions & embrace listening, you open yourself up to learning from different people/populations. Ask THEM what’s important to them, to better serve them. #patientchat |
 | Jamie Roger @JamieRoger8 Sorry I'm late to the party #patientchat Jamie here from CT, representing @salemoaks |
| Science 37 @Science37x RT @power4patients: T4: T4: Diversity is critically important but we have to keep in mind that overall < 5% of eligible patients participate in #clinicaltrials. LESS THAN 5%! I think the solution partially lies in telling the stories of "patient pioneers" Here's 1: https://t.co/piF4SW3mU4 #patientchat |
| Science 37 @Science37x RT @KisteinM: A4: A4: Invest more into reaching, engaging and recruiting minority populations. Collaborate with non traditional partners such as community based organizations, as well as minority patient advocacy groups, religious organization,etc. #patientchat https://t.co/iDtn9M2BTP |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey @ShereesePubHlth Brave woman! Go for it #patientchat |
| Science 37 @Science37x RT @anetto: @Justinrt4444 Yes, and look at representation of minorities among researchers and clinicians as well. We want to see ourselves represented on team. #PatientChat |
| Dr. Phyllisa Deroze @not_defeated A5. You have to know your audience. For my diabetes support group, I have snacks & a play area for kids because I want moms to be able to attend. Something that small goes a long way. Understand the person you want to attract. #patientchat https://t.co/zRmca1L5wj |
| Science 37 @Science37x RT @gratefull080504: A5: @patientchat : A5: @patientchat : That is the inherent problem of moving to tactics first without a #patientengagement strategy Strategy first if you want to address root issues not symptoms #patientchat https://t.co/pD7OwwziMu |
| Tebra @TebraOfficial RT @HealSuffering: Underrepresented populations in minority and rural communities may not have adequate information to participate in clinical trials. In addition, the lack of info may lead them to believe it would cost them to partake. #patientchat https://t.co/Hm7hRx1xsR |
| Science 37 @Science37x RT @TechKitsune: A5: A5: At some point everyone has a story and wants to be listened to. Outreach in communities is impactful because it is human interaction with the thought of helping someone who didn't know there were opportunities. #patientchat #HITsm |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 A5: #patientengagement strategy, strategy, strategy, etc. #patientchat https://t.co/pD7OwwziMu |
| Christina Lizaso @btrfly12 RT @anetto: @Justinrt4444 Yes, and look at representation of minorities among researchers and clinicians as well. We want to see ourselves represented on team. #PatientChat |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @katie5280: @patientchat T4: @patientchat T4: Specifically market to areas with those populations, especially rural areas. Not everyone uses social media, so sending flyers or info via USPS could be helpful. #patientchat |
| Christina Lizaso @btrfly12 RT @power4patients: T4: T4: Diversity is critically important but we have to keep in mind that overall < 5% of eligible patients participate in #clinicaltrials. LESS THAN 5%! I think the solution partially lies in telling the stories of "patient pioneers" Here's 1: https://t.co/piF4SW3mU4 #patientchat |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @gratefull080504: A5: @patientchat : A5: @patientchat : That is the inherent problem of moving to tactics first without a #patientengagement strategy Strategy first if you want to address root issues not symptoms #patientchat https://t.co/pD7OwwziMu |
| Patient Chat @patientchat Topic 6 (T6:) coming up...https://t.co/lRhU0PEGMz #patientchat |
| Science 37 @Science37x RT @not_defeated: A5. You have to know your audience. For my diabetes support group, I have snacks & a play area for kids because I want moms to be able to attend. Something that small goes a long way. Understand the person you want to attract. #patientchat https://t.co/zRmca1L5wj |
 | Claire Snyman @clairehsnyman RT @BarbyIngle: A2: A2: Clinical trials need 2 better mirror PTs who will b the user. Especially on DX that appear diff n minority pops. If we dont develop diverse pool of research pts, health disparities may persist We wont know if med is safe & effective n those that ultimately use it #patientchat https://t.co/zodJXmcHNS |
| Ken Taylor, RPIC @KenRayTaylor RT @BarbyIngle: A5: A5: The data of the people who are tracked for specific conditions can be used in recruitment, marketing to those PTs specifically, and developing treatment options through trials that help the actual PT population at greatest risk for disease complications #patientchat https://t.co/afeE6nGmi3 |
| Vera Rulon FAHIMA @vrulon @anetto @Justinrt4444 That's a very important point. A report by the Sullivan Commission discusses the importance of diversity in the health professions. Titled: MISSING PERSONS: MINORITIES IN THE HEALTH PROFESSIONS #patientchat https://t.co/R4BJEOS0KP … |
| Patient Chat @patientchat T6: What stakeholders should be involved ensuring diverse clinical trials? What is their role and how can they collaborate? #patientchat |
| Vera Rulon FAHIMA @vrulon T5: @not_defeated mentioned #culture - apply tactics that work with a given population after understanding their needs & wants - @iCANResearch is a great example - also leveraging the communication channels that resonate #patientchat |
| Shereese Maynard, MS; MBA 😷 She/Her @ShereeseMayMba RT @vrulon: @anetto @Justinrt4444 That's a very important point. A report by the Sullivan Commission discusses the importance of diversity in the health professions. Titled: MISSING PERSONS: MINORITIES IN THE HEALTH PROFESSIONS #patientchat https://t.co/R4BJEOS0KP … |
| Jamie Roger @JamieRoger8 RT @vrulon: @gratefull080504 Great point. Same goes for so many other diseases/conditions. Clinical trial participants should reflect the diversity (down to %) of given populations who suffer these diseases. #patientchat |
| Ken Taylor, RPIC @KenRayTaylor A5: Use the tracked data to form your media in a more meaningful way so it sounds like your talking to me and target the population your after. #patientchat https://t.co/jTlUYc4L0l |
| Heather McCullen @H_SalemOaks @HealSuffering This is a problem in general. Making information more available is critical. #patientchat |
| Annette McKinnon @anetto @PatientIntv Agree with @patientlntv. Portals might make a great way to inform people about trials and to raise health literacy. #patientchat |
| Patient Empowerment Network @power4patients RT @patientchat: T6: T6: What stakeholders should be involved ensuring diverse clinical trials? What is their role and how can they collaborate? #patientchat |
| Kistein Monkhouse, MPA @KisteinM A5: Study the population carefully, target populations by incorporating #Sdoh. Gender disparities differs greatly from age disparities and race disparities. #patientchat https://t.co/WdXE3xCXjh |
| Barby Ingle Official @BarbyIngle RT @KenRayTaylor: A5: A5: Use the tracked data to form your media in a more meaningful way so it sounds like your talking to me and target the population your after. #patientchat https://t.co/jTlUYc4L0l |
| Christina Lizaso @btrfly12 RT @TechKitsune: A5: A5: At some point everyone has a story and wants to be listened to. Outreach in communities is impactful because it is human interaction with the thought of helping someone who didn't know there were opportunities. #patientchat #HITsm |
| Barby Ingle Official @BarbyIngle A6: Stakeholders should include the trial coordinators, researchers, data collection companies, NPO patient orgs for that disease, patients, caregivers #patientchat https://t.co/Y2mAIdqZg1 |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey General observation: PPRNs (Patient Powered Research Networks) and CDRNs (Clinical Data Research Networks) are emerging community-facing, have seen tangible diversity within them. #clinicalresearch #patientchat |
| Patient Empowerment Network @power4patients #patientchat |
| Jamie Roger @JamieRoger8 RT @TechKitsune: A5: A5: At some point everyone has a story and wants to be listened to. Outreach in communities is impactful because it is human interaction with the thought of helping someone who didn't know there were opportunities. #patientchat #HITsm |
| Shereese Maynard, MS; MBA 😷 She/Her @ShereeseMayMba RT @MightyCasey: General observation: General observation: PPRNs (Patient Powered Research Networks) and CDRNs (Clinical Data Research Networks) are emerging community-facing, have seen tangible diversity within them. #clinicalresearch #patientchat |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 A5: I will respond with another question @patientchat Who are trying to serve with your clinical trial? If you can answer that truthfully, you know who your stakeholders are #patientchat https://t.co/tR7nztOMf5 |
| Jamie Roger @JamieRoger8 RT @not_defeated: A5. You have to know your audience. For my diabetes support group, I have snacks & a play area for kids because I want moms to be able to attend. Something that small goes a long way. Understand the person you want to attract. #patientchat https://t.co/zRmca1L5wj |
| Patient Chat @patientchat RT @BarbyIngle: A6: A6: Stakeholders should include the trial coordinators, researchers, data collection companies, NPO patient orgs for that disease, patients, caregivers #patientchat https://t.co/Y2mAIdqZg1 |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 #patientchat Have to run Thanks @patientchat |
| Mary MACK @MaryOCMack T5: pay people for joining #patientchat |
| Shereese Maynard, MS; MBA 😷 She/Her @ShereeseMayMba T6 All of them! #patientchat |
| Ken Taylor, RPIC @KenRayTaylor RT @BarbyIngle: A6: A6: Stakeholders should include the trial coordinators, researchers, data collection companies, NPO patient orgs for that disease, patients, caregivers #patientchat https://t.co/Y2mAIdqZg1 |
| Christina Lizaso @btrfly12 RT @MightyCasey: General observation: General observation: PPRNs (Patient Powered Research Networks) and CDRNs (Clinical Data Research Networks) are emerging community-facing, have seen tangible diversity within them. #clinicalresearch #patientchat |
| Jamie Roger @JamieRoger8 @not_defeated Awesome setuo, not to mention the amount of stress that decreases for your participants. #patientchat #human #relationships |
| Patient Chat @patientchat RT @gratefull080504: A5: A5: I will respond with another question @patientchat Who are trying to serve with your clinical trial? If you can answer that truthfully, you know who your stakeholders are #patientchat https://t.co/tR7nztOMf5 |
| Science 37 @Science37x Type 2 Diabetes research hasn’t always represented everyone. You can change that #T2D #diabetes https://t.co/hwReBcg0Hg #patientchat |
| Shereese Maynard, MS; MBA 😷 She/Her @ShereeseMayMba RT @Science37x: Type 2 Diabetes research hasn’t always represented everyone. You can change that #T2D #diabetes https://t.co/hwReBcg0Hg #patientchat |
| Lieutenant O'Purra @HealSuffering Communication and understanding of cultural practices could possibly improve participation in clinical trials. Translators that understand the cultural idiosyncracies that may exist regarding medical care could help increase diversity. #patientchat https://t.co/2XHJNgVxT5 |
| Science 37 @Science37x RT @vrulon: @anetto @Justinrt4444 That's a very important point. A report by the Sullivan Commission discusses the importance of diversity in the health professions. Titled: MISSING PERSONS: MINORITIES IN THE HEALTH PROFESSIONS #patientchat https://t.co/R4BJEOS0KP … |
| Science 37 @Science37x RT @patientchat: T6: T6: What stakeholders should be involved ensuring diverse clinical trials? What is their role and how can they collaborate? #patientchat |
| Science 37 @Science37x RT @vrulon: T5: T5: @not_defeated mentioned #culture - apply tactics that work with a given population after understanding their needs & wants - @iCANResearch is a great example - also leveraging the communication channels that resonate #patientchat |
| iPain Foundation Research Projects @iPain_Research RT @BarbyIngle: A5: A5: The data of the people who are tracked for specific conditions can be used in recruitment, marketing to those PTs specifically, and developing treatment options through trials that help the actual PT population at greatest risk for disease complications #patientchat https://t.co/afeE6nGmi3 |
| iPain Foundation Research Projects @iPain_Research RT @KenRayTaylor: A5: A5: Use the tracked data to form your media in a more meaningful way so it sounds like your talking to me and target the population your after. #patientchat https://t.co/jTlUYc4L0l |
| Patient Chat @patientchat @gratefull080504 Thank you for joining Kevin - enjoy your weekend! #patientchat |
| iPain Foundation Research Projects @iPain_Research RT @BarbyIngle: A6: A6: Stakeholders should include the trial coordinators, researchers, data collection companies, NPO patient orgs for that disease, patients, caregivers #patientchat https://t.co/Y2mAIdqZg1 |
| Science 37 @Science37x RT @KisteinM: A5: A5: Study the population carefully, target populations by incorporating #Sdoh. Gender disparities differs greatly from age disparities and race disparities. #patientchat https://t.co/WdXE3xCXjh |
| Science 37 @Science37x RT @MightyCasey: General observation: General observation: PPRNs (Patient Powered Research Networks) and CDRNs (Clinical Data Research Networks) are emerging community-facing, have seen tangible diversity within them. #clinicalresearch #patientchat |
| Science 37 @Science37x RT @BarbyIngle: A6: A6: Stakeholders should include the trial coordinators, researchers, data collection companies, NPO patient orgs for that disease, patients, caregivers #patientchat https://t.co/Y2mAIdqZg1 |
| International Pain Foundation® @iPainOfficial RT @BarbyIngle: A5: A5: The data of the people who are tracked for specific conditions can be used in recruitment, marketing to those PTs specifically, and developing treatment options through trials that help the actual PT population at greatest risk for disease complications #patientchat https://t.co/afeE6nGmi3 |
| International Pain Foundation® @iPainOfficial RT @KenRayTaylor: A5: A5: Use the tracked data to form your media in a more meaningful way so it sounds like your talking to me and target the population your after. #patientchat https://t.co/jTlUYc4L0l |
| International Pain Foundation® @iPainOfficial RT @BarbyIngle: A6: A6: Stakeholders should include the trial coordinators, researchers, data collection companies, NPO patient orgs for that disease, patients, caregivers #patientchat https://t.co/Y2mAIdqZg1 |
| Science 37 @Science37x RT @gratefull080504: A5: A5: I will respond with another question @patientchat Who are trying to serve with your clinical trial? If you can answer that truthfully, you know who your stakeholders are #patientchat https://t.co/tR7nztOMf5 |
| Vera Rulon FAHIMA @vrulon @patientchat A6: Stakeholders - #patients & their #caregivers - ID what matters, communities/churches - disseminate information & improve #trust, #researchers - provide information & reduce biases in their circles, #regulators - ensure regs that protect #patientchat |
| Patient Chat @patientchat RT @HealSuffering: Communication and understanding of cultural practices could possibly improve participation in clinical trials. Translators that understand the cultural idiosyncracies that may exist regarding medical care could help increase diversity. #patientchat https://t.co/2XHJNgVxT5 |
| Science 37 @Science37x RT @HealSuffering: Communication and understanding of cultural practices could possibly improve participation in clinical trials. Translators that understand the cultural idiosyncracies that may exist regarding medical care could help increase diversity. #patientchat https://t.co/2XHJNgVxT5 |
| Science 37 @Science37x RT @vrulon: @patientchat A6: @patientchat A6: Stakeholders - #patients & their #caregivers - ID what matters, communities/churches - disseminate information & improve #trust, #researchers - provide information & reduce biases in their circles, #regulators - ensure regs that protect #patientchat |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @Science37x: Type 2 Diabetes research hasn’t always represented everyone. You can change that #T2D #diabetes https://t.co/hwReBcg0Hg #patientchat |
| Lieutenant O'Purra @HealSuffering @H_SalemOaks So true. There needs to be cooperation between personal physicians and the clinic running the trials. #patientchat |
| Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @not_defeated: A5. You have to know your audience. For my diabetes support group, I have snacks & a play area for kids because I want moms to be able to attend. Something that small goes a long way. Understand the person you want to attract. #patientchat https://t.co/zRmca1L5wj |
| Science 37 @Science37x @patientchat @gratefull080504 Great chatting with you, Kevin! #patientchat |
| Vera Rulon FAHIMA @vrulon @JECallender @GetSocialHealth Couldn't agree more. #challenge #patientchat |
| Geeky Fox @TechKitsune RT @BarbyIngle: A6: A6: Stakeholders should include the trial coordinators, researchers, data collection companies, NPO patient orgs for that disease, patients, caregivers #patientchat https://t.co/Y2mAIdqZg1 |
 | Jeremy Murphy @jeremypmurphy RT @patientchat: T6: T6: What stakeholders should be involved ensuring diverse clinical trials? What is their role and how can they collaborate? #patientchat |
| Ken Taylor, RPIC @KenRayTaylor A6: Trial coordinators , patient organizations, patients and care givers should be involved. #patientchat https://t.co/hZo5RKiLMa |
| Patient Chat @patientchat Time to start sharing closing thoughts (CT) on what you learned, were reminded of or can implement. Start your tweet w/ CT: #patientchat |
| Alan Brewington @abrewi3010 A6 before stakeholders are identified lets spend more time on the trial question. We need better/more human centered quests for QOL. #patientchat |
| Jeremy Murphy @jeremypmurphy RT @patientchat: T5: T5: How will those tactics be used across different ages, races and genders? #patientchat |
| Jeremy Murphy @jeremypmurphy RT @patientchat: T4: T4: How can researchers improve engagement and recruitment of minority patient populations? #patientchat |
| Jeremy Murphy @jeremypmurphy RT @patientchat: T3: T3: What are some of the barriers to diversifying clinical trials? #patientchat |
| Jeremy Murphy @jeremypmurphy RT @patientchat: T2: T2: Why do you think it is important to diversify clinical trials? #patientchat |
| Barby Ingle Official @BarbyIngle RT @KenRayTaylor: A6: A6: Trial coordinators , patient organizations, patients and care givers should be involved. #patientchat https://t.co/hZo5RKiLMa |
| Jeremy Murphy @jeremypmurphy RT @patientchat: T1: T1: Why do you think there is so much disparity in enrollment of minority patient populations in clinical trials? #patientchat |
| Kistein Monkhouse, MPA @KisteinM 👌There’s a clear divide between those that are privileged to be a part of the conversation let alone the trials themselves. #LGBTQ populations 👋 #elderly #racial and #ethnic #minorities 👋 #poverty stricken populations 👋#patientchat https://t.co/JnLn4zW482 |
| Science 37 @Science37x RT @patientchat: Time to start sharing closing thoughts (CT) on what you learned, were reminded of or can implement. Start your tweet w/ CT: #patientchat |
| International Pain Foundation® @iPainOfficial RT @KenRayTaylor: A6: A6: Trial coordinators , patient organizations, patients and care givers should be involved. #patientchat https://t.co/hZo5RKiLMa |
| Shereese Maynard, MS; MBA 😷 She/Her @ShereeseMayMba RT @KisteinM: 👌There’s a clear divide between those that are privileged to be a part of the conversation let alone the trials themselves. #LGBTQ populations 👋 #elderly #racial and #ethnic #minorities 👋 #poverty stricken populations 👋#patientchat https://t.co/JnLn4zW482 |
| Science 37 @Science37x RT @KisteinM: 👌There’s a clear divide between those that are privileged to be a part of the conversation let alone the trials themselves. #LGBTQ populations 👋 #elderly #racial and #ethnic #minorities 👋 #poverty stricken populations 👋#patientchat https://t.co/JnLn4zW482 |
| Christina Lizaso @btrfly12 Closing Thoughts - Ala today's #HITsm chat earlier, don't underestimate the power of storytelling in bringing about change. Increasing diversity in #clinicaltrials won't just happen - needs champions and thoughtful collaboration. #patientchat |
| Jamie Roger @JamieRoger8 @HealSuffering @H_SalemOaks Having worked in a clinic that had mediocre communication between the clinical trial #researchers and the clinical staff, it is CRUCIAL that everyone is on the same page. Otherwise #patients get lost or aren't treated with the best care. #patientchat #brokensystem |
 | Regina Holliday @ReginaHolliday RT @KisteinM: A3: A3: cultural competency is a huge barrier in clinical trials. I.e are you meeting patients at their levels, is staff/recruiters speaking the language, comprehends the make disparities that vulnerable populations face, etc.. #patientchat https://t.co/D2Ny4C6tPd |
| Regina Holliday @ReginaHolliday RT @KisteinM: A3: A3: barriers to diversifying clinical trials can be locations I.e reaching those living in rural areas. #patientchat https://t.co/D2Ny4C6tPd |
| Regina Holliday @ReginaHolliday RT @vrulon: A3: Add to already mentioned barriers: A3: Add to already mentioned barriers: bureaucratic processes in current trials & lack of automation (but very slowly getting better); and most importantly - not including patients in trial design. Include patients and diversity will improve. #patientchat |
| Regina Holliday @ReginaHolliday RT @ShereesePubHlth: @KisteinM This is a huge problem . Many clinical trial teams have no buy-in to underserved communities and there's no attempt to include person who do have that buy-in. #patientchat |
#patientchat content from Twitter.